Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Aegerion Pharmaceuticals Announces Proposed Public Offering of Common Stock

Aegerion Pharmaceuticals Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Jan. 10, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals,
Inc. (Nasdaq:AEGR) ("Aegerion"), a biopharmaceutical company dedicated to the
development and commercialization of innovative, life-altering therapies for
patients with debilitating and often fatal rare diseases, today announced that
it intends to offer for sale its common stock in an underwritten public
offering. All shares in the offering are being sold by Aegerion. The offering
is subject to market conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or terms of
the offering.      

Jefferies & Company, Inc. and J.P. Morgan Securities LLC are acting as joint
book-running managers in the offering.

The securities described above are being offered by Aegerion pursuant to a
shelf registration statement previously filed with and declared effective by
the Securities and Exchange Commission (the "SEC"). A preliminary prospectus
supplement related to the offering will be filed with the SEC and will be
available on the SEC's website at Copies of the
preliminary prospectus supplement and the accompanying prospectus relating to
these securities may be obtained, when available, from Jefferies & Company,
Inc., Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor,
New York, NY, 10022, or by telephone at 877-547-6340, or by email at; or J.P. Morgan Securities LLC, c/o
Broadridge Financial, 1155 Long Island Avenue, Edgewood, New York 11717 or by
telephone at 1-866-803-9204.

This release shall not constitute an offer to sell or the solicitation of an
offer to buy these securities, nor shall there be any sale of these securities
in any state or other jurisdiction in which such offer, solicitation or sale
would be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the
development and commercialization of innovative, life-altering therapies for
patients with debilitating, often fatal, rare diseases.

The Aegerion Pharmaceuticals, Inc. logo is available at

Forward-Looking Statements

This press release contains forward-looking statements, including statements
regarding the completion and timing of Aegerion's proposed public offering of
common stock. These forward-looking statements are neither promises nor
guarantees of future performance, and are subject to a variety of risks and
uncertainties, many of which are beyond Aegerion's control, which could cause
actual results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and uncertainties
include, among other factors: risks and uncertainties associated with market
conditions and satisfaction of customary closing conditions related to the
proposed offering, risks associated with Aegerion's ability to satisfy
Aegerion's obligations to close the proposed offering and the risk that
Aegerion will not use the proceeds from the offering in the manner
contemplated. For additional disclosure regarding these and other risks, see
the disclosure contained in Aegerion's public filings with the SEC (available
on the SEC's website at, including the "Risk Factors"
section of Aegerion's Current Report on Form 8-K filed on January 10, 2013 and
in the preliminary prospectus supplement and related prospectus relating to
the proposed offering to be filed with the SEC. Aegerion undertakes no
obligation to update or revise the information contained in this press
release, whether as a result of new information, future events or
circumstances or otherwise. 

CONTACT: Aegerion Pharmaceuticals, Inc.
         Michael Lawless, VP, IR
         + 1 (857) 242-5028

Aegerion Pharmaceuticals, Inc. Logo
Sponsored Links
Sponsored Links